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ABSTRACT 
 
OBJECTIVE: 
To study the maternal and fetal outcome in early onset severe 
preeclampsia and to note the variable factors associated with maternal 
and fetal morbidity and mortality. 
STUDY DESIGN: 
It was a prospective analytical study conducted at Institute of 
Obstetrics and Gynaecology with a sample size of 150 patients who 
had severe preeclampsia between 24 to 34 weeks. 
METHODS: 
Patients who met the inclusion  criteria were included in the 
study. Detailed history, examination and investigations were done. 
Details regarding the treatment and the mode of termination are noted. 
Follow up of mother and neonate  done  upto discharge / death. 
 
 
RESULTS: 
More common in Primigravida in the age group of 21-30 years. 
Mean gestational age  at diagnosis was 31 weeks. Most of the women 
underwent termination after 32 weeks 84(56%).Maternal indication was found 
to be the most  common cause for termination in 128 (85.3%)women, Imminent 
eclampsia being commonest.104(69%) had caesarean section.32 women in the 
study group underwent expectant management with maximum prolongation of 
25 days.There were no maternal death in patients who were managed 
expectantly but 4 patients had morbidity and there were 2 fetal mortality and 9 
morbidity in the expectant management group. Mean birthweight was 1.43 
kg.Out of 150 babies 90(60%) had complications. There were 16 neonatal death 
and 4 stillbirth with perinatal mortality rate of 30%. 58 (38.6%) women of the 
total study group experienced complication.Eclampsia and abruption were 
higher.There were 6(4%) maternal death. Mean postpartum hospital stay was 16 
days. 
CONCLUSION: 
Early onset severe preeclampsia is associated with significant maternal 
and fetal complications Decision regarding termination of pregnancy has to be 
taken based on both maternal and fetal factors. Termination should be done 
irrespective of fetal maturity in case of severe uncontrolled blood pressure with 
complications. In selected cases expectant management in a tertiary care centre 
limit the impact of serious maternal and fetal complications. 
 
KEY WORDS: 
 Early onset severe preeclampsia, Imminent Eclampsia, 
Expectant management,Maternal outcome, Fetal outcome, Perinatal 
mortality. 
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INTRODUCTION 
 Preeclampsia is a multisystem disorder involving placenta, 
kidney, liver, blood, cardiovascular and neurovascular system, 
occurring exclusively during pregnancy whose etiology is not known.  
It occurs in approximately 5-7% of pregnancies.  It is an important 
cause of morbidity as well as mortality in both the mother and fetus. 
 Preeclampsia is described as a rise in blood pressure and 
proteinuria which is of new onset, occuring after 20 weeks of 
gestation.  It is described as severe preeclampsia if there is substantial 
increase of blood pressure and proteinuria or the occurrence of 
symptoms due to end organ damage.  Preeclampsia is considered early 
onset if elevation of blood pressure and proteinuria occur before 34 
weeks of pregnancy.  Hypertension and its complications is ranked 
third as a leading cause of maternal mortality, responsible for over 
17% of maternal deaths 1,2,3 .Even in developed countries, women still 
die from pre – eclampsia and eclampsia. 
 There is increased risk of acute renal failure, cardiovascular and 
cerebrovascular complications, abruptio placenta, disseminated 
intravascular coagulation and even maternal death1.  So, early 
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diagnosis and close monitoring in preeclampsia plays a vital role in 
preventing its complications. 
 In case of early onset severe preeclampsia, there is progressive 
deterioration in the health condition of mother and also high morality 
in the fetus2,3 during the perinatal period.  Delivery the fetus is 
considered the only way to revert all these complication.  So, 
termination of pregnancy is needed  if there is fetal distress, in case of 
multi organ dysfunction or if the gestation age reaches 34 weeks.  But, 
prematurity due to early termination causes high perinatal morbidity 
and mortality1,5,6.  Accelerated fetal lung maturation does not occur in 
preeclampsia8 however expectant management to prolong pregnancy 
can be deleterious to the mother7,9.  Hence, potential benefits attained 
for the fetus should be weighed against the potential dangers that 
occur to the mother. 
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AIM OF THE STUDY 
1) To study the maternal and fetal outcome in early onset severe 
preeclampsia. 
2)       To note the variable factors associated with maternal and fetal 
morbidity and mortality. 
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REVIEW OF LITERATURE 
HISTORICAL  ASPECTS: 
Pre- eclampsia is a complex disease often labeled as “disease of 
theories” due to numerous schools of thought. 
Eclamptic convulsions have been recognized in ancient 
Chinese, Indian, and Greek literature dating back 4000 years. 
Hippocrates around 400 BC stated headache accompanied by 
convulsions during Pregnancy was considered bad. 
Bossier de saurages (1739) introduced the word Eclampsia and 
differentiated eclampsia from epilepsy. 
Demanet (1797) recognised swelling in eclamptic women.  
Pierre Rayer (1840) discovered protein in urine while John Lever 
(1843) reported Proteinuria was specific Pre-eclampsia. 
  Vasquez and Nobcourt (1897) discovered eclamptic 
hypertension. 
Chesley (1984) said Sensory stimuli were reduced by keeping 
the patients is dark quite room. Horn (1906) first used magnesium 
sulphate to manage pre-eclampsia – Eclampsia. 
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Lazard and Dorsett (1920) popularized the parental use of 
magnesium sulphate only in 1990. Major studies demonstrated the 
superiority of magnesium superheat over other anticonvulsants. 
In 1967, Robertson and Brosens described structural changes of 
the utero placental unit in pre-eclampsia.   
MAGNITUDE OF THE PROBLEM: 
Pre- eclampsia has a prevalence rate of 2.3%12. 50% of the 
women with severe pre-eclampsia present at less than 34 weeks of 
gestation.   Delivery is mandatory either for maternal or fetal reasons 
within 24 hours of admission. 
CLASSIFICATION: 
National High Pressure Education program 2000 classification 
is as follows: 
• Gestational Hypertension 
• Pre eclampsia 
• Eclampsia 
• Superimposed Pre eclampsia 
• Chronic Hypertension 
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DEFINITIONS 
PRE-ECLAMPSIA 
Pre-eclampsia is defined as rise in systolic pressure of 140 
mmHg or greater or diastolic pressure of 90 mmHg or greater that 
develops for the first time in pregnancy after 20 weeks of gestation in 
atleast two occasions accompanied by proteinuria. 
Proteinuria   defined as 0.3g or more of urinary protein per 24 
hours or persistent 30 mg/dL (1+ dipstick) in a random urine sample. 
Severe Pre-eclampsia: 
Severe pre-eclampsia is defined as hypertension (diastolic blood 
pressure   ≥ 110 mm Hg) with proteinuria (≥5gm in 24 hours urine 
specimen or ≥ 3+ on a dipstick). 
Early onset severe pre- eclampsia: 
When severe pre- eclampsia develops prior to 34 weeks of 
gestation14. 
ACOG CRITERIA FOR SEVERE PREECLAMPSIA: 
  Severe Pre eclampsia is considered in the presence of one or 
more of the following  
• Blood pressure- systolic of 160 mmHg or greater or diastolic of 
110 mmHg or greater on atleast two occasions, 6 hours apart. 
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• Proteinuria  of  5gm or more in 24 hours urine sample or 3+ or 
higher on atleast two random urine  samples collected  4 hours 
apart  
• Oliguria (<500 ml in 24 hours). 
• Pulmonary edema or cyanosis. 
• Cerebral or visual disturbances. 
• Thrombocytopenia 
• Liver  dysfunction 
• Epigastric Pain 
• Fetal growth restriction. 
RISK FACTORS: 
The most predictive risk factors of pre- eclampsia  were mean 
arterial pressure and Parity.  The risk with mean arterial pressure was 
8% when < 75mm Hg and 27% if > 85 mm Hg.  Risk was 26% is 
nulliparous where as 17% in parous patients15. 
There is increased risk of pre- eclampsia in women with 
periodontal disease are and systemic inflammation early in pregnancy 
with (CRP ≥ 75th percentile)17. 
Recent study demonstrated a significant association between 
maternal thrombophilia   and severe preeclampsia18. 
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Maternal and paternal genetic factors increase the risk of pre 
eclampsia. 
Pregnancy associated:  
- Chromosomal abnormalities 
- Hydatidiform mole  
- Hydrops fetalis 
- Multiple gestations.  
Maternal specific: 
- Primi parity 
- Age < 20 & > 35 Yrs. 
- Previous pre-eclamptic 
- BMI > 35 
- Family history of pre-eclampsia. 
- Gestational diabetes or pre-existing diabetes. 
- Chronic hypertension. 
- Nephropathy. 
- Thrombophilias. 
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Paternal Specific: 
- First time father 
- Previously fathered a pre-eclampsia pregnancy is another 
woman. 
ETIOPATHOGENESIS: 
Various theories have been proposed in the causation of pre 
eclampsia. 
- Abnormalities in the trophoblastic invasion. 
- Genetic  predisposition 
- Role of vasoactive agents 
- Immunological theory 
- Oxidative stress and inflammatory changes 
- Endothelial factor. 
Abnormal trophoblastic invasion: 
Normally the uterine spiral arteries are invaded by endovascular 
trophoblasts. In pre-eclampsia there is incomplete trophoblastic 
invasion22.  In a recent study of placental morphology, placentas from 
early onset (<34 weeks) and late onset (>34 weeks) were studied. An 
abnormal placental morphology was found in early onset, whereas 
placentas from late onset disease were morphologically similar to 
those from same gestational age controls. 
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Dewolf et al examined the arteries from utero-placental 
implantation site.  They observed early pre- eclamptic changes which 
include endothelial damage, proliferation of myointimal cells, 
insudation of plasma constituents into vessel walls and medial 
necrosis.  These changes results in diminished placental perfusion, 
leading to pre-eclampsia syndrome.   
Genetic Predisposition: 
A multi factorial inheritance has been reported. 
An association between HLA DR4 and protienuric hypertension 
has been reported. 
 
11 
 
 
 
Immunological theories: 
These theories are based on incompatibility at the feto-maternal 
interface.  There is disruption of equilibrium between fetal genotype 
and maternal immune responses required for normal placentation. 23 
• Absence of blocking antibodies - There is an imbalance 
between the ratio of fetal antigenic load and maternal blocking 
antibodies.  This might be due to excess fetal antigen load 
12 
 
(hydatiform mole, multiple gestations) or absence of blocking 
antibodies (as in first pregnancy). 
Role of vasoactive agents: 
In pre-eclampsia there is an increase in Thromboxane A2 and 
decrease in prostacyclin (PGI2) and prostaglandin E2 resulting is 
vasoconstriction24.  
Endothelin – 1 which is a potent vasoconstrictor is found to be 
increased in  pre- eclampsia25. 
Vascular endothelial growth factor causes vasculogenesis and 
important for microvascular permeability.  It is found be increased in 
pre- eclampsia26. 
Endothelial factor: 
Endothelial cell dysfunction is a major factor in the 
pathogenesis of pre- eclampsia. 
Nitric oxide which is a potent vasodilator is decreased in pre 
eclampsia27. 
Elevated homocysteine   level in early pregnancy increases risk 
of pre eclampsia. 
Inflammatory change and oxidative stress: 
Pre- eclampsia occurs due to extreme stage of activated 
leucocytes in the maternal circulation.  Deciduas when activated 
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releases leukotreines, TNF Alfa which result in oxidative stress in the 
body.  
There is release of oxygen free radicals due to oxidative stress 
in pre- eclampsia which result in 
- Release of lipid laden macrophages 
- Damage to endothelium 
- Activation of micro vascular coagulation 
- Increased capillary permeability.  
PATHO PHYSIOLOGICAL CHANGES: 
Hemodynamic Changes: 
In Pre-eclampsia,   
a) Cardiac preload decreases due to generalized vasospasm22  
b) Cardiac after load increases due to increase in vascular 
resistance. 
c)  MAP is reduced as there is increase is peripheral vascular 
resistance. 
Hematological Changes22: 
a) Thrombocytopenia – occurs in 10 to 25 % of women having 
pre-eclampsia.  It is probably immunologically mediated or 
because of increase in platelet deposition at the endothelial 
damage site. 
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b) Hyper coagulation is pre-eclampsia is due to  
• Increased activity of intrinsic factors. 
• Increased platelet aggregation. 
• Increased thrombin – Anti thrombin ratio. 
• Decreased anti thrombin III and fibrinogens. 
 
Endocrine changes: 
In Pre-eclampsia there is suppression of renin- angiotensin -
aldosterone axis and sodium retention is increased22.  
Fluid Changes: 
Extra cellular fluid volume increases as a result of endothelial 
damage leading to proteinuria and edema22.  
PREDICTORS OF PRE ECLAMPSIA: 
1. Mean arterial pressure is  better than systolic or diastolic blood 
pressure as a predictor for pre eclampsia.  The mean arterial 
pressure during first trimester is elevated in women who 
develop pre-eclampsia99  
2. As a marker of early onset severe pre-eclampsia, reduced level 
of placental growth factor (PIGF) in first trimester is most 
sensitive as well as specific. 
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3. Uterine artery Doppler evaluation is combination with soluble 
fms-like tyrosine kinase (SFlt – 1); placental growth factor 
(PIGF) and Angogenic factors may be useful as a second 
trimester screening test for early onset pre- eclampsia. 
4. Soluble Endoglin (SEng) is elevated in pre- eclampsia. 
Combination of Sflt – 1 and SEng is a good predictor of early 
onset pre- eclampsia in second trimester with 100% sensitivity. 
5. Serum activin  A  and inhibin A are elevated  before 20 weeks 
in women developing early onset revere preeclampsia. 
6. Higher HCG, MSAFP, lower MSUE3 are significant markers of 
early onset severe pre- eclampsia93. 
7. Placental oxidative stress is associated with early onset pre- 
eclampsia. There is an increase in PAI – 1 / PAI - 2 ratios which 
suggest a stronger link between early onset pre- eclampsia and a 
dysfunctional placenta. 
8. Women with several pre- eclampsia have higher plasma 
concentration of adiponectin. 
9. Total 25 – hydroxy vitamin D (25 – 0H – D) level is decreased 
is women developing early onset severe pre-eclampsia. To 
understand the impact of vitamin D on pregnancy outcomes, 
further studies are needed. 
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Maternal Outcome: 
Women with Severe Pre-eclampsia are at increased risk for 
abruptio placenta, acute renal failure, disseminated intravascular 
coagulation, cerebral haemorrhage, pulmonary edema, circulatory 
collapse28. 
Murphy and stirrat29 studied 71 preeclamptic women with 
gestational age less than 30 weeks and reported 21% had developed 
HELLP syndrome, 15% had abruptio placenta, 13% had renal failure 
and 1.4% eclampsia but no maternal mortality was observed.  
Al –Mulhim et al reported that the commonest complication to 
be abruptio placenta.  
Perinatal Outcome: 
Perinatal outcome is usually dependent on one or more of the 
following: 
1. Gestational age at the time of delivery. 
2. Gestational age at the onset of pre eclampsia. 
3. Present of multiple gestation. 
4.  Severity of the disease. 
5. Presence of other medical disorders. 
17 
 
Pre-eclampsia accounts for more than 40% of pre-mature 
deliveries31 and there is a substantial increase in the risk of low birth 
weight and SGA babies 32,33,34,35,. 
In a study performed by odegard et al36 compared 307 live 
singleton born to pre eclamptic women to 619 controls, pre-eclampsia 
and severe preeclampsia were associated with a 5% and 12% 
reduction in birth weight respectively, and birth weight was 23% 
lower than expected. 
Magee et al37 in a multi centric retrospective study found out 
that 16% of pre-eclampsia pregnancies being complicated by birth 
weight less than third percentile. 
Very low birth weight (VLBW less than 1500 grms) and 
extremely low birth weight (ELBW, less than 1000 grms) babies often 
require re-admission to hospital in the first two years for respiratory 
infections38. 
EXPECTANT MANAGEMENT: 
There have been 15 non randomized non controlled trials to 
assess the benefits of expectant management in pregnancy between 24 
to 34 weeks and showed an average of 10 – 14 days prolongation  of 
pregnancy in cases of severe preeclampsia without increase in 
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maternal morbidity but these trials are not reliable as they lack 
randomization41. 
However, since 1990 only one maternal death has been reported 
in literature among 1677 women who underwent expectant 
management40. 
RCOG AND ACOG RECOMMENDATIONS: 
AIM:-   
To prolong pregnancy in severe preeclampsia women remote 
from term in order to improve perinatal outcome without increasing 
maternal  morbidity or mortality. 
PLACE:- 
Management is best accomplished in a tertiary care setting with 
senior obstetric consultants, obstetrician gynecologists trained in 
management of high risk pregnancy, experienced staff.  Candidates 
depend on a number of factors like maternal and fetal conditions as 
well as gestational age42. There is no place for expectant management 
in gestational age <26 weeks as there is increase in perinatal and 
maternal morbidity and mortality43. 
Expectant Management in IUGR: - studies have showed that in 
women with server pre-eclampsia at 24 – 33 weeks IUGR is 
associated with high risk of fetal mortality but does not cause maternal 
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complications47 and may benefit from prolongation of pregnancy  
beyond 48 hours that is required for the action of steroids. 
Expectant management in HELLP Syndrome: 
Current evidence demonstrates that women with HELLP 
syndrome should not be managed expectantly.  Vaginal or caesarean 
delivery should be pursued as appropriate.  Antenatal steroids may be 
given concurrently. 
TERMINATION OF PREGNANCY: 
Termination is needed is the following conditions. 
FETAL:- 
Severe  IUGR 
Non reassuring fetal surveillance  
Oligohydromnios  
Maternal:- 
Abruptio  placenta  
Platelets < 1 lakh 
Progressive detoriation of liver and renal function 
Signs and Symptoms of imminent eclampsia. 
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GUIDELINES FOR MANAGEMENT 
FETO – MATERNAL MONITORING: 
During initial assessment, blood pressure should be measured 
every 15 minutes till the woman is stabilized and later to be checked 
every 30 minutes. 
Later measurement of blood pressure should be done at least 
four times per day. 
CBC with platelet count, LDH,AST,ALT repeated everyday 
and more frequently in case of abnormalities. 
If platelet count is above 1,00,000 cells/dL, clotting studies are not 
needed. 
Input and output charting is vital in monitoring fluid balance, 
especially in the immediate postpartum period. 
ASSESSMENT OF FETUS: 
Fetal Monitoring includes fetal heart rate monitoring with 
cardiotocography which gives information regarding well being of the 
fetus. Continuous fetal monitoring should be done in women in labour. 
Fetal biometry, umbilical and cerebral Doppler and liquor volume 
should be measured for further assessment. Delivery time can be 
assessed based on serial measurements. Investigation with Doppler 
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evaluation using absent or reversed umbilical artery (UA) diastolic 
flow improves neonatal outcome 50 .  Its serial measurements can 
optimize time of delivery. 
NON PHARMACOLOGICAL APPROACHES  
Although no study or clinical trial which clearly gives the data 
about the use of restricted activity in severe preeclampsia, but it is 
considered good clinical practice to restrict activity and hospitalize 
these patients. 
ROLE OF ANTI – HYPERTENSIVES: 
Anti hypertensive treatment should be started when there is 
elevation of blood pressure to severe range (>160/110mmHg).  With 
severe disease, anti hypertensive treatment should be considered even 
in lower measurements.  For acute management, oral or intravenous 
labetolol, oral nifedipine or intravenous hydralazine can be used. 
Angiotensin converting enzyme inhibitors, atenolol, diuretics 
and angiotensin receptor blocking drugs are avoided. 
Nifedipine is used orally not sublingually. Randomized trails 
doesnot support the general consensus that treatment is required when 
blood pressure is higher than 170/110mm Hg52.  However it is 
desirous to prevent vascular damage as a result of uncontrolled 
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hypertension.  A lower threshold of 160 mm Hg systole is suggested 
by enquiries into maternal death. 
ROLE OF MAGNESIUM SULPHATE: 
Magnesium sulphate remains the anticonvulsant of choice in 
any kind of set up.  Magnesium sulphate has been shown to decrease 
the progression of pre – eclampsia to eclampsia by more than fifty 
percent 44. 
Pritchard regime is usually followed, which include 20ml of 
20% magnesium sulphate (which is equivalent to 4gm) is given as a 
loading dose by intravenous route over 10 minutes.   Later 10ml of 
50% magnesium sulphate (which is equivalent to 5gm) by 
intramuscular route in alternative buttock given every four hours as 
maintenance therapy 45. 
If convulsions recur, further addition of 2 to 4gm is given by 
intravenous route over 5 minutes.  Therapeutic level of 4-6 mg is to be 
maintained. 
Before administrating the subsequent doses, the women should 
be checked for 
- Urine output at least 100ml over the last four hours. 
- Knee jerk   
- Respiratory rate of atleast 16 per minute. 
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If any of the above parameters are found to be abnormal, the 
subsequent dose should be delayed till attainment of normal status.  In 
case of toxicity, 10ml of 10% calcium gluconate (1gm) is given by 
intravenous route over 10 minutes and oxygenation provided.  
In case of persistence of convulsions patient should be 
transferred to intensive care unit and if necessary maintained with 
intermittent positive pressure ventilation. 
ROLE OF STEROIDS: 
It is a well known fact that antenatal glucocorticoids decreases 
neonatal morbidity as well as mortality in a woman with severe 
disease at or less than 34 weeks of gestation age 46. 
Previously, it was uncertain whether steroids were efficacious in 
severe pre-eclampsia less than 34 weeks of gestation. However, a 
prospective randomized trial showed that there was significant 
reduction in the incidence of respiratory distress syndrome (RR, 0.53; 
95%CI, 0.35 to 0.82) in the Steroids group (receiving betamethasone) 
against the control group (receiving placebo)46 Thus steroids help in 
fetal lung maturity and should be used for at least 48 hours. Their use 
has also been reported in cases of HELLP syndrome as they prolong 
pregnancy 58 and lead to resolution of hematological and biochemical 
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abnormality. But their role in reducing morbidity is uncertain 
according to another study 57. 
FLUID BALANCE: 
Large majority of women with mild pre – eclampsia have 
expanded intravascular volume.  Hence to avoid fluid overload, fluids 
should be restricted to about 1ml / kg/ hour or 80ml / hour. 
Inappropriate fluid management has often been associated with 
pulmonary edema which has attainted significance as an important 
cause of maternal death 53.   
Fluid expansion provides no benefit 59. While fluid restriction 
have showed good outcome60.  Fluid restriction is inappropriate in 
case of maternal hemorrhage or oliguria. 
MODE OF DELIVERY: 
There are no randomized trails conducted for comparing the 
ideal method for delivery in pre-eclamptic women. 
Vaginal delivery should be attempted in all women with mild 
pre-eclampsia and in most women with severe pre-eclampsia, 
provided there is no other indication for caesarean section 5. Pre-
eclampsia as such is not an indication for caesarean section. 
In a study of Gofton et al in 2001 showed that induction of labour and 
caesarean section in women with gestational hypertension is twice as 
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those in the control group and were also similar to pre-eclampsia and 
chronic hypertension. But, the study did not show any differentiation 
between mild/severe and early/late of gestation. 
Induction of labour with prostaglandins will increase the chance 
of vaginal delivery. Throughout labour, assessment and anti 
hypertensives should be continued. 
POSTPARTUM MANAGEMENT: 
Postnatal close monitoring should be done for women with 
severe disease .  The period of hospital stay is unclear as eclampsia 
can occur even after 4 weeks postnatal.  However  after fourth 
postpartum day, incidence of eclampsia decrease 54. 
Inpatient management for four or more days will be required for 
most women with severe disease after delivery. 
Anti – hypertensive treatment should be continued and tapered 
stepwise after delivery.  It can take even three months for blood 
pressure to return back to normal.  No particular anti – hypertensive is 
recommended. But α- methyl dopa is avoided due to its side effect, 
like depression.  Nifedipine, labetolol, enalapril and atenolol are being 
used currently in breastfeeding women. 
Women should be further investigated in case of persistence of 
high blood pressure and proteinuria. 
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PROPHYLAXIS: 
In 2003, Duley et al found that there is decrease in risk of pre – 
eclampsia by 19% and 16% reduction in fetal and neonatal deaths with 
the use of aspirin . 75mg aspirin daily started after first trimester may 
be offered as a prophylaxis for women at high risk of developing 
hypertension, (e.g., abnormal uterine artery Doppler, previous 
pregnancy with pre  eclampsia, pre – existing hypertension, etc.,) 63, 64. 
A small randomized trial (Chappell et al ) demonstrated a 
decrease in pre – eclampsia incidence in women using vitamins C & 
E.  However pre – eclampsia prevention using antioxidants require 
larger trial for assessing the safety and benefits of this treatment. 
Systemic review of 11 randomized controlled trials (Atallah et 
al, 2002) shows that with calcium, there is significant decrease in risk 
of hypertension and also pre – eclampsia. 
LONG TERM OUTCOME AFTER PREECLAMPSIA. 
CARDIOVASCULAR DISEASE AND HYPERTENSION: 
Higher are the chances of developing cardiovascular diseases 
and / or chronic hypertension later in life in a woman with history of 
pre – eclampsia.67, 68. 
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In 1995, nissel described that women appear to have chronic 
hypertension 7 years after a pregnancy complicated by hypertension 
when compared with a control group 67. 
Wilson et al 69 reported that there is association between 
pregnancy induced hypertension and hypertension related diseases in 
later life, like stroke. 
Irgens et al70, in the study conducted in Norway with 6,26,272 
live births between 1967 and 1992, showed that there is 8.12 times 
higher risk of death due to cardiovascular disease in women with 
preterm delivery and pre eclampsia than in the reference group. 
Sattar and Greer 71 in 2002 suggested that there is high risk 
for cardiovascular disease in later life in a woman with adverse 
pregnancy outcomes and described that both may have common 
mechanisms 71. 
RENAL DISEASE: 
There is frequent association of pre – eclampsia in a women 
with pre – existing renal diseases 72.  Post  partum renal biopsy studies 
showed the classic renal lesion of pre – eclampsia e.g., glomerular 
endotheliosis.  Also lesions like nephrosclerosis or other abnormalities 
were found in primigravida at a rate of 9.2% and in multigravida at a 
rate of 37% 68. 
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Reiter et al, found that only 2.3% women with pre – eclampsia 
had renal disease in their follow up between three months and six 
years 72.  Jacquemyn et al found that there is no difference in renal 
dysfunction between women with HELLP syndrome followed up for 5 
or more years and control group who were normotensive during their 
pregnancy 73.  
  Another report which studied the long term renal function in 
women who had pregnancy with pre eclampsia or HELLP syndrome 
described that there is no effect of pre – eclampsia on long term renal 
function 74. 
 
HEPATIC DISEASE: 
Liver is not primarily involved in pre – eclampsia while liver 
involvement is observed in only 10% of women with severe pre – 
eclampsia .  One of the severe manifestation of pre – eclampsia is 
HELLP syndrome. 
The hepatic findings in HELLP syndrome consist of focal 
parenchymal necrosis and periportal necrosis 75.  The most likely 
reason is hepatic ischemia which results in deposition of fibrin in the 
hepatic sinusoids.  In the hepatocellular necrotic areas, there is 
infiltration of red blood cells and inflammatory cells.  Though there is 
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considerable damage to the liver parenchyma, it usually recovers 
within six weeks of postpartum period, which results in regeneration 
of parenchyma of the liver. 
As a result of subcapsular hematoma, there may be rupture of 
the liver capsule which occurs very rarely but is a severe life 
threatening complications due to HELLP syndrome.  There is 
complete recovery of liver function in those who survive this 
complication and in some women, there are reports of successful 
pregnancy also.  The recurrence risk is however unknown76. 
BRAIN LESIONS: 
The pathophysiology of neurological disturbances in case of  
pre–eclampsia is least understood.  The most frequent location of 
specific lesions are the parieto – occipital lobes which is also the 
anatomic location of petechial hemorrhages and infarction.  While 
most of these lesions were found to be reversible, others were reported 
to be permanent.  Utilizing the modern imaging methods, the lesions 
were found to be ischemic with resulting small infarcts in the brain 
i.e., gliosis.  Long term follow up of neurological functions in these 
patients is currently under investigation. 
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SIMILAR RISKFACTORS OF PRE – ECLAMPSIA AND 
ATHEROSCLEROSIS: 
In a woman with pre – eclampsia and / or HELLP syndrome, 
there is enhanced risk for venous and arterial diseases 77. 
Even after adjustment for other risk factors of coronary artery 
disease.  Pre – eclampsia is found to be an independent risk factor 72.  
With a strong family history of cardiovascular disease, more likely is 
the chance to develop hypertension of pregnancy and pre–eclampsia78.  
There is high chance of preterm birth and intrauterine growth 
retardation when associated with maternal stress during pregnancy. 
The only exception is smoking which is protective against 
pre – eclampsia where as it is a risk factor for cardiovascular disease.  
Pre – eclampsia, preterm delivery, low birth weight and a combination 
of these factors can be a first manifestation in case of atherosclerosis. 
Bogges et al 80 reported that there may be transient translocation 
of oral microbial flora to the utero- placental unit of pregnant women 
with periodontal disease, leading to oxidative stress in early pregnancy 
or inflammation of placenta, which result in clinical manifestations of 
pre – eclampsia and produced placental damage. 
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RECURRENCE RISK: 
The recurrence risk of developing hypertension in subsequent 
conception is about 20-50%, while that of developing HELLP 
syndrome is about 2 to 6%. 
  The major predictors of subsequent conception are gestational 
age and birth weight. The gestational age will be longer by 5 weeks 
and birth weight 1300 to 1400g more in the subsequent conception 
independent of the recurrence 81. 
PSYCHOSOCIAL CONSEQUENCES IN PRE – ECLAMPSIA 
AND HELLP SYNDROME: 
There is an increased risk of post traumatic stress disorder 
(PTSD) as a result of the unexpected complications that occurs during 
pregnancy.  PTSD manifestations include sleeplessness, irritability, 
exaggerated startle response, avoiding situations, increased arousal, re- 
experiencing the event,etc., 
Engelhard 82 reported that pre – eclampsia is a primary cause 
but not an exclusive cause for PTSD which results from concomitant 
preterm delivery. 
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MATERIALS AND METHODS 
STUDY DESIGN: 
Prospective Analytical Study 
SETTING: 
Institute Of Obstetrics And Gynecology 
Egmore 
Chennai-8. 
 
SAMPLE : 
150 patients with  pregnancies complicated by EARLY ONSET 
SEVERE PREECLAMPSIA at IOG for a period of one and a 
half  years (2012-2013).  
INCLUSION CRITERIA: 
1. Gestational age >=24weeks and < 34 weeks 
2. Diastolic BP >= 110 mmHg 
3. Proteinuria  >= 3+ 
 
with any of the following 
 
4. Persistent headache 
5. Blurred vision 
6. Eclampsia 
7. Elevated liver enzymes 
8. Low Platelets 
9. Abruptio Placenta 
10. Oligohydomnios 
11. IUGR 
 
  
33 
 
EXCLUSION CRITERIA: 
1. Gestational age < 24weeks and  > 34 weeks 
2. Preexisting  chronic  renal  and hepatic disease. 
3. Idiopathic  hemolytic  anaemia  
4. Idiopathic  thrombocytopenic  purpura 
5. Epilepsy  
 
METHOD: 
All patients who meet the above mentioned criteria were 
included in the study and patients were admitted in the intensive care 
unit . 
Patient's detailed history, symptoms and signs of severe 
preeclampsia ,imminent eclampsia were noted. 
General and Obstetric examination was carried out. 
Urine investigation and PIH profile was done on admission and 
repeated based upon the progression of the disease. 
Obstetric ultrasound with fetal doppler were  performed in 
patients on expectant management.In case of any abnormalities like 
Doppler changes, oligohydromnios and IUGR then expectant 
management was discontinued and planned for termination. 
Details regarding treatment ( Antihypertensives, Mgso4, 
steroids) were noted. 
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Details regarding mode of termination and indication for 
termination, Intraoperative,postpartum complications were noted. 
Neonatal assessment was done by following the babies in the 
NICU.Maternal complications were noted.  Follwup of mother and 
neonate  done  upto discharge / death. 
Collected datas were tabulated and statistical analysis 
performed. 
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TABLE: I 
AGE DISTRIBUTION 
NUMBER OF 
PATIENTS PERCENTAGE
33 
90 
27 
22 
60 
18 
150 100 
– 30 (60%).  
with a range of 17 yrs - 40 yrs. 
 
 
 
 PARITY 
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Most of the patients were primi,  n=99 (66%)
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TABLE : II 
PARITY 
NUMBER OF 
PATIENTS 
PERCENTAGE
99 
51 
66
34
150 100
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Out of 150 patients 148 (98.6%) were booked and 2 (1.3%) 
were unbooked 
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TABLE : III 
ANTENATAL VISITS 
 NUMBER OF 
PATIENTS 
PERCENTAGE
148 
2 
98.7
1.3
150 100
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SOCIOECONOMIC STATUS
SOCIOECONOMIC CLASS
SOCIOECONOMIC CLASS
I 
II 
III 
IV 
V 
Total 
Most of the women belonged to social economic class IV and V.
38 
1
85
TABLE: IV 
 
 NUMBER 
OF 
PATIENTS 
PERCENTAGE
… 
… 
1 
85 
64 
… 
… 
0.7 
56.7
42.6
150 100 
 
III
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V
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This table includes gestational age at which the patient first fulfilled 
the inclusion criteria for severe preeclampsia.
Most of women n = 7
gestational age at diagnosis was 31 weeks with 
weeks. 
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TABLE : V 
GA AT DIAGNOSIS 
NUMBER OF 
PATIENTS 
PERCENTAGE
21 
53 
76 
14 
35.3 
50.7 
150 100 
 
 
6 (50.7%) were in 32 – 34 weeks 
a range of 25 to 34 
 
 
Mean 
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Most of the Women underwent termination of pregnancy after 32 
weeks 84(56%) 
Mean gestational age at the time of delivery was 32 weeks.  
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TABLE – VI 
GA AT DELIVERY 
 NUMBER OF 
PATIENTS 
PERCENTAGE
13 8.7 
51 34 
84 56 
2 1.3 
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Investigations
INVESTIGATIONS
TABLE : VII 
INVESTIGATIONS:- 
 NUMBER OF 
PATIENTS 
PERCENTAGE
78 
30 
23 
30 
33 
12 
52
20
15.3
20
22
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Out of 150 patients, 104 (69.3%) women received Mgs04, out 
of which 4 developed seizures 3 of them had Post partum eclampsia.
 46 (30.7%) women did not received Mgs04, out of which 11 
(23.4%) developed seizure.
symptoms and signs.  In 26 cases Mgs04 was given in view of high 
BP without imminent symptoms.
MGS04 
Received 
Not Received 
42 
46
Not Received
Mgso4 
TABLE : VIII 
MGS04 : 
 
 
  Mgs04 was given in view of imminent 
 
NUMBER OF 
PATIENTS 
PERCENTAGE
104 
46 
69.3
30.7
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ANTI HYPERTENSIVES:
ANTIHYPERTENSIVE
Oral 
Parenteral 
 All women in this study group received oral antihypertensive 
(methyldopa with Nifedipine  or Labetalol  with Nifedipine)
 33 women (22%) required parenteral antihypertensive 
(Labetalol or Nitroglycerine) for control of blood pressure.
 Out of 150 women, 72 (48%) women were on oral 
antihypertensive before admission.
43 
33
117
Parenteral Both
TABLE : IX 
- 
S NUMBER OF 
PATIENTS 
PERCENTAGE
150 
33 
100
22
 
 
 
 
 
 
 
 
 
 
 INDICATION FOR TERMINATION OF PREGNANCY 
INDICATION
Maternal 
Fetal 
Maternal indication was found to be the most common cause for 
termination of pregnancy, 128 (85.3%) most common cause being 
imminent eclampsia.  Most common fetal indication was Doppler 
changes.  
 
INDICATION FOR TERMINATION
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TABLE – X 
 
 NUMBER OF 
PATIENTS 
PERCENTAGE
128 85.3
22 14.7
 
 
85%
15%
 
 
 
 
Maternal
Fetal
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INDICATIONS FOR TERMINATION ARE THE FOLLOWING: 
MATERNAL 
1. Signs of imminent eclampsia 
2. Eclampisa 
3. Uncontrolled hypertension in spite of oral and parenteral anti-
hypertensive 
4. Abruptio placenta  
5. Abnormalities in renal function test  
6. HELLP Syndrome  
7. DIVC 
FETAL 
1. Doppler abnormalities  
2. Severe oligohydromnios 
3. IUGR  
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TABLE – XII 
MODE OF DELIVERY 
GA AT DELIVERY VAGINAL CAESAREAN TOTAL 
24-28 7 6 13 
28-32 19 32 51 
32-34 20 64 84 
>34 0 2 2 
TOTAL 46 104 150 
 
Out of 150 patients, 69 ( 46%) were induced. 
Out of  69 patients who were induced , 46 (30.7 %)  delivered 
vaginally and 23 (15.3%) underwent caesarean section.Out of 25 
IUFDs, 9 were delivered by caesarean section  indication  being  
Abruption  for 7 and eclampsia for 2 patients. 
81(54%)  patients were not induced and underwent  direct 
caesarean  section.  The causes were Imminent eclampsia,  eclampsia , 
Abruption, Doppler changes, severe oligohydromnios. 
Overall , total number of patients who underwent  LSCS were 
,104(69 %) 
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69%
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TABLE – XII 
EXPECTANT MANAGEMENT 
GA AT 
DIAGNOSIS 
NUMBER OF 
PATIENTS 
EXPECTANT 
MANAGEMENT 
NUMBER OF 
PATIENTS 
PERCENTAGE 
24-28 21 8 38.1 
28-32 53 9 16.9 
32-34 76 15 19.7 
TOTAL 150 32 21.3 
 
Out of 150 patients in this study 32(21.3%) patients underwent 
expectant management. Maximum prolongation of pregnancy was 25 
days.  
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TOTAL NUMBER 
OF PATIENTS 150
76
150
9
15
32
-32 32-34 TOTAL
TOTAL NO OF 
PATIENTS
EXPECTANT 
MANAGEMENT
 
 6
2
0
2
4
6
8
10
12
14
16
24-28
PROLONGATION OF PREGNANCY
PROLONGATION OF PREGNANCY
GA AT 
DIAGNOSIS 
 
24-28 
28-32 
32-34 
TOTAL 
 
Out of 32 patients, 27(87.4%) patients had a prolongation of 
pregnancy ≤ 10 days. Maximum prolongation was 25 days. Mean 
number of days gained was 7 days with a range of 1 
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TABLE – XIII 
 
NO OF DAYS GAINED TOTAL
1-10 11-20 >20 
6 2  
7 1 1 
14 0 1 
27 3 2 
– 25 days.
 
1-10
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>20
 
 
8 
9 
15 
32 
 
51 
 
0
10
20
30
40
50
60
70
80
90
100
24 – 28 28 – 32 32 – 34
PE
R
C
EN
TA
G
E
GA AT DIAGNOSIS (WEEKS)
GA AT DIAGNOSIS Vs OUTCOME
Maternal Morbidity and 
Mortality
Fetal Morbidity and 
Mortality
TABLE : XIV 
GA AT DIAGNOSIS Vs OUTCOME: 
GA at Diagnosis 
(Weeks) 
Number 
of 
Patients 
Maternal 
Morbidity and 
Mortality 
Fetal Morbidity 
and Mortality 
No % No % 
24 – 28 21 11 52.3 20 95.2 
28 – 32 53 20 37.7 37 69.8 
32 – 34 76 25 32.8 33 43.4 
Total 150 58 38.6 90 60 
Both maternal and fetal morbidly and mortality were more 
during early gestational age, 52.3%and 95.2% at gestational age  
24 – 28 weeks respectively.  Overall fetal morbidity was more than 
maternal morbidity. 
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TABLE – XV 
GA AT DELIVERY (VS) FETAL MORBIDITY AND 
MORTALITY(Excluding 25 IUFDS) 
GA AT 
DELIVERY 
(Weeks) 
 
        RDS 
 
        HIE 
 
       IUGR 
 
       PND 
NO % NO % NO % NO % 
24-28  (13) 4 30.7 1 7.69 1 7.69 5 38.4 
28-32  (51) 7 13.7 5 9.8 6 11.7 10 19.6 
32-34  (84) 11 13 4 4.76 9 10.7 5 6 
>34      (2) -  -  -  -  
 
Fetal morbidity and mortality was found to be high at early 
gestational age,38.4% perinatal death at 24 – 28 weeks where as it is 
6% at 32- 34 weeks.RDS was high between 24-28  and 28-32 
weeks,30.7% and 13.7% respectively. P value  < 0.05, statistically 
significant.There was positive correlation between geastational age at 
delivery and fetal morbidity and mortality. 
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MATERNAL
TABLE – XVI             MATERNAL OUTCOME
MATERNAL 
OUTCOME 
Eclampsia 
Abruption 
Wound Infection 
DEATH 
Post partum 
eclampsia 
HELLP 
DIVC 
ARF 
Atonic PPH 
TOTAL 
 
58 (38.6%) women experienced complications. Eclampsia and 
abruption were highest accounting to 17(11.3%)  and 14(9.3%) 
respectively.There were  6 (4%) maternal death in this study.All the 
six maternal death were between the gestational age of 30 to 34 
weeks.    
53 
8 6 3 3 3 2 2
OUTCOME
 
NUMBER OF 
PATIENTS 
PERCENTAGE
17 11.3 
14 9.3 
8 5.3 
6 4 
3 2 
3 2 
3 2 
2 1.3 
2 1.3 
58 38.6 
 
 
 
 
 1
1
1
MATERNAL DEATH
CAUSES OF MATERNAL 
DEATH
HELLP / DIVC 
AP Eclampsia with hypertensive 
failure 
AP Eclampsia with ARF 
Severe preeclampsia with 
pulmonary edema 
Abruption with DIVC
TOTAL 
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2
1
HELLP/DIVC
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AP  ECLAMPSIA WITH 
ARF
SEVERE 
PREECLAMPSIA WITH 
PULMONARY EDEMA
ABRUPTION WITH DIVC
TABLE – XVII 
MATERNAL DEATH 
 
NUMBER OF PATIENTS
2 
1 
 1 
1 
 1 
6 
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TABLE – XVIII 
FETAL OUTCOME 
FETAL OUTCOME NUMBER OF 
BABIES 
PERCENTAGE 
IUFD 25 27.8 
IUGR 15 16.6 
Death 16 17.8 
RDS 13 14.4 
HIE 2 1.3 
RDS +HIE 9 10 
SEPTICEMIA 6 6.7 
STILLBORN 4 4.5 
TOTAL 90 100 
 
Out of the total 150 babies , 90(60%) babies had complication. 
Out of 90 babies 25(16.6%) were IUFDs,majority were in women who 
were  referred as IUFDs.Cause of IUFD being abruption in majority of 
cases.121 babies were born alive. All were preterm. Major cause for 
neonatal morbidity and mortality were prematurity and Respiratory 
distress syndrome.Out of 21 babies who had RDS, 13(62%) did not 
receive steroids and 8(38%) received steroids. Neonatal ICU 
admission were needed in 90% of babies. Neonatal deaths  were  
16(10.6%) 
PN Mortality and Morbidity 
Total no of  babies       150 
No of live babies         121 
No of  IUFDs               25 
No of Stillbirth              4 
No of Neonatal death   16 
 60
25
FETAL OUTCOME
Normal, 60
Total Perinatal death 
Incidence of PNM Total PND /No of babiesX 100 
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30% 
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Out of 121 babies (excluding 25 IUFDs and 4 stillborn), 71 
(47.3%) babies had apgar of 5
with increasing gestational age, which was statistically significant 
with P value <0.002.  
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TABLE – XIX 
 
 
APGAR 
0 1-4 5-7 8
7 2 4 
16 3 23 
7 6 43 
0 0 1 
30 11 71 
-7. Apgar was found to be improving 
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GA AT DELIVERY Vs BIRTH WEIGHT
GA AT 
DELIVERY 
 500
24-28 
28-32 
32-34 
>34 
TOTAL 
 
Low birth weight, defined as 1.5
cases very low birth weight 1
low birth weight <1kg was seen in 17 (11.3%) cases. Mean birth 
weight was 1.43kg with a range of 500 grms to 2300 grms. IUGR wa
seen in 23(19.1%) babies. 
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TABLE – XX 
 
BIRTH WEIGHT IN GRAMS 
-999 1000-1499 1500-
1999 
2000
9 4 - 
7 33 9 
1 16 54 
- - 2 
17 53 65 
-2.5kg was seen in 65 (43.3%) 
-1.5Kg was seen in 53 (35.3%) extreme 
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BIRTH WEIGHT (VS) FETAL OUTCOME
BIRTH WEIGHT (VS) FETAL OUTCOME (Excluding 25 
BIRTH 
WEIGHT 
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1000-1499 15 
1500-1999 10 
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There is rapid fall in death rate and perinatal morbidity as birth 
weight increases. 
PND was 100% in birth weight <1 kg where as there was no 
perinatal death in birth weight >2 kg.
significant.There was a positive 
outcome 
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TABLE – XXI 
IUFDS) 
 
RDS 
 
PND ALIVE
 % NO % NO 
 7 100  
35.7 10 23.8 32 
16.3 3 4.9 58 
 -  14 
 p value is<0.001 statistically 
correlation between birth weight and 
 
RDS
PND
ALIVE
 
 
% 
 
76.1 
95 
93.3 
 Fetal Morbidity 
and 
Mortality, 11
EXPECTANT MANAGEMENT (VS) FETAL 
EXPECTANT MANAGEMENT  (VS) FETAL OUTCOME
 
PROLONGATION
OF PREGNANCY
(DAYS) 
1-10     (27) 
11-20   (3) 
>20  (2) 
TOTAL (32) 
 
Out of 32 patients who had expectant management there was 
9(28.1%) and 2(6.2%) fetal morbidity and mortality 
respectively.There were no still birth.
Two neonatal death occurred in patient who were delivered at 
29 weeks. 
60 
Normal, 21
OUTCOME
TOTAL ---32
TABLE – XXII 
 
 
FETAL 
MORBIDITY 
FETAL
MORTALITY
NO % NO 
7 25.9 1 
2 66.9 1 
- -      - 
9 28.1 2 
 
 
 
 
% 
3.7 
33.3 
- 
6.2 
 EXPECTANT MANAGEMENT  (VS) MATERNAL OUTCOME
 
MATERNAL 
COMPLICATIONS
Eclampsia 
HELLP 
ARF 
PP Eclampsia 
 
Out of 32 patients who had expectant management there were no 
maternal death, and 4(12.5%) patients had 
were delivered by caesarean section.
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TABLE – XXIV 
POST OP BP CONTROL 
BP CONTROL NUMBER OF 
PATIENTS 
PERCENTAGE 
<3 DAYS 18 12.5 
3-7 107 74.3 
8-14 16 11.1 
>14 3 2.1 
 
In majority of the patients BP control was achieved within a week. 
only 7 patients were discharged with antihypertensives. 
TABLE – XXV 
POSTPARTUM HOSPITALISATION 
NO OF DAYS NUMBER OF 
PATIENTS 
PERCENTAGE 
<7 5 3.5 
7-14 69 45.8 
15-28 69 47.9 
>28 4 2.8 
 
Most of the women required hospitalisation for 2 to 3 weeks with a 
minimum of 7 days and a maximum of 31 days. 
Mean of postpartum hospital stay was 16 days. 
Prolonged hospitalisation in most of the women was for baby sake 
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DISCUSSION 
Preeclampsia affects both mother and neonate. It is one of the 
leading cause of maternal and fetal morbidity and mortality. 
AGE: 
Sixty (60%) of the women in the study group were in the age 
group of 21 to 30 years, which correlates with the studies of  
Moodley83 in which the mean age was 26 years.In studies done by 
Brown MA and Buddle ML33, D.R.Hall14  the mean  age was 26 
years.In our study mean age was 26 years. 
PARITY: 
 Preeclampsia is common in first pregnancy.More than half the 
women in this study were Nulliparous, 99 (66%). Brown MA and 
Buddle ML33 said preeclampsia is predominant in nulliparous. 
RISK FACTORS: 
Only forty three (28.6%) of the women in this study group had 
risk factors, which includes gestational hypertension in previous 
pregnanacy and family history of hypertension. 
In the study by  D.R.Hall14  36% of the women had risk factors. 
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ANTENATAL VISITS: 
Almost one forty eight (98.6%) women in this study were 
booked either at our institution or outside. 108 (68%) were booked 
outside and referred to IOG. 
Adequate antenatal care has an important role in reducing the 
complications by early detection and appropriate management. 
Though most of  the patients in this study were  booked , early 
detection of gestational hypertension was not made because  one or 
two recordings of high blood pressure  at early gestational age was not 
taken into serious consideration and also because of  unawareness of 
the  women. 
SOCIOECONOMIC STATUS: 
Most of the women , 85 (56.7%) and 64(42.6%) belonged 
tosocioeconomic class IV and V respectively.  
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GA AT DIAGNOSIS: 
 Mean gestational age  at diagnosis was 31 weeks in our study.  
AUTHOR GA AT DIAGNOSIS(WEEKS) 
D.R.Hall 30 
Brown MA and Buddle ML 27 
J.Moodley and Daya 32 
Our study 31 
 
There was a positive correlation between gestational age at 
diagnosis and the Fetal outcome. 
Earlier the onset of preeclampsia greater is the fetal 
complications, 95.2% at 24 to 28 weeks compared to 43.4% after 32 
weeks. 
INVESTIGATIONS: 
  Serum uric acid  was found to be high in 52% of the 
patients.Uric acid is used as an indicator of disease severity and a 
good predictor in  determining the outcome of the fetus than blood 
pressure21. 
Platelet count less than 100,000mm3 is considered as an 
indicator of severity of  preeclampsia31,85.In this study 15.3% of the 
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women had a low platelet count.Platelet count is decreased because of 
increase in consumption and destruction inside the vessel lumen86. 
 Coagulation profile was altered in 11(7.3%) and  30 (20%) 
patients had altered renal functions.Fundal changes of grade I and 
grade II were found in 33 (22%) of patients in which Grade I  and 
Grade II were 22(14.7%) and 11(7.3) respectively.There were no 
ophthalmic indications like papilledema and retinal detachment  for 
termination of pregnancy. 
MAGNESIUM  SULPHATE : 
Magnesium sulphate reduces the risk of maternal mortality and 
the risk of seizures88. Magnesium sulphate was given to 69.3% of 
severe preeclampsia in our study which is low compared to other 
studies88,89.In a  study by Lee WO’ Connell CM and Baskett  97% of 
the patients received magnesium sulphate 89. 
Magnesium sulphate when given to patients with severe 
preeclampsia reduces the risk of seizures by 58%.But routine 
prophylaxis in patients with severe preeclampsia is questioned and the 
decision is based on the method of treatment whether conservative or 
immediate termination. 
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ANTIHYPERTENSIVE AGENTS: 
In this study all patients received oral hypertensives either 
Methyldopa and nifedipine or  labetolol and nifedipine. 33 (22%) 
patients required  parenteral antihypertensives in addition to oral 
antihypertensive. 
 In all patients  who required parenteral antihypertensive 
magnesium sulphate was given and seizures didnot occur. 
GESTATIONAL AGE AT DELIVERY: 
Most of the women underwent termination of pregnancy at 32-
34 weeks , 84(56%).In the study by D.R.Hall14 GA at the time of 
delivery was found to be 32-34 weeks.Apgar was found to be 
improving with increasing  gestational age. 
Fetal morbidity and mortality was found to be high at early 
gestational age,38.4% perinatal death at 24 – 28 weeks where as it is 
6% at 32- 34 weeks.RDS was high between 24-28  and 28-32 
weeks,30.7% and 13.7% respectively. 
Dehram et al34 showed improvement in neonatal survival with 
increasing gestational age. 
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TERMINATION OF PREGNANCY: 
Maternal indication was found to be the most common cause for 
termination of pregnancy in 128(85.3%) patients and the fetal cause in 
22(14.7%).Imminent eclampsia was the most common cause of 
maternal indication for termination..In the study by Blackwell SC in 
2002, termination was done for  maternal indication  in 80% and for 
fetal indication in 20% of the patients. 
Though preeclampsia is one of the risk factor for prematurity, 
the cause of prematurity in most of the cases is iatrogenic either 
induction of labour or caesarean section to prevent morbidity and 
mortality in mother and fetus 
MODE OF DELIVERY: 
Though delivery is the ultimate cure for preeclampsia, fetal 
outcome should be taken into consideration in the absence of maternal 
complication21,86. 
Almost 69% of the women in this study were delivered by 
caesarean section. 
This rate is higher than that reported by Mashiloane and 
Moodley83  but similar to that of Hall et al where 81.5% delivered by 
means of caesarean section14. 
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STUDY VAGINAL 
DELIVERY 
CAESAREAN 
Hall et al 18.5% 81.5% 
Murphy DJ 20% 80% 
Nassar et al 48.3% 51.7% 
Railton and Allen 25% 75% 
Our study 31% 69% 
 
Our  study correlates with that of   Railton less than that of  Hall 
and Murphy and higher than Nassar. 
FETAL PARAMETERS: 
APGAR: 
 Out of 120 babies (excluding 25 IUFDs and 4 stillborn), 71 
(47.3%) babies had apgar of 5-7.  
Apgar was found to be improving with increasing gestational 
age.Only 5.6% babies had apgar of 5-7 at 24 to 28 weeks. 
BIRTH WEIGHT: 
Low birth weight, defined as 1.5-2.5kg was seen in 65 (43.3%) 
cases very low birth weight 1-1.5Kg was seen in 53 (35.3%) extreme 
low birth weight <1kg was seen in 17 (11.3%) cases. Mean birth 
weight was 1.43kg. 
The mean birth weight was 1.4 kg in the study by D R Hall et 
al14 , 1.62 kg in the study by Sibai et al. 
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 There is rapid fall in death rate and perinatal morbidity as birth 
weight increases. PND was 100% in birth weight <1 kg where as there 
was no perinatal death in birth weight >2 kg. 
Odendal et al90 showed improving perinatal survival as birth rate 
increases. 
 
MATERNAL OUTCOME: 
 Ultimate goal in the management of severe preeclampsia must 
first be the safety of the mother and second the delivery of a live infant 
who will not require prolonged neonatal care. 
 In our study maternal morbidity and mortality was seen in 
38.6%. Eclampsia and abruption were highest accounting to 
17(11.3%)  and 14(9.3%)  respectively.Other complications were 
HELLP,DIVC,ARF. 
In our study Maternal mortality was  6 (4%) .In study 
conducted by Manisha et al in New delhi in 2012 reported maternal 
mortality of 1.8% in their study . 
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STUDY ABRUPTION PULMONARY 
EDEMA 
HELLP ECLAMPSIA RENAL 
FAILURE 
DR Hall 20% 2% 5% 1.2% 0.3% 
Vissur and 
Wellenberg 
5% - - 1.9% - 
Murphy DJ 1.5% - 21% 1.4% 1.3% 
Olah and 
edman 
- - 14.2% - 3.5% 
Manish et 
al 
1.9% 1.9% 10.4% 12.8% - 
Our study 10% 1.3% 3.3% 14.6% 2% 
 
PERINATAL OUTCOME: 
Total Perinatal death IUFD+SB+ND  45.   
Incidence  of  PNM Total PND  / No of babies  X  100 30% . 
 The neonatal outcome depends on the intensive care facilities 
and the gestational age at birth.Witlin et al94 reported that neonatal 
outcome in early onset severe preeclampsia was directly correlating 
with increasing birth weight and Respiratory distress syndrome 
reduced with increasing gestational age. 
In our study 90% babies required neonatal ICU.Major neonatal 
complications were Hyaline membrane disease, HIE,IUGR, 
Septicemia,and neonatal death. 
The administration of antenatal steroid has shown significant 
reduction in neonatal morbidity and mortality. Out of 21 babies who 
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had RDS, 13(62%) did not receive steroids and 8(38%) received 
steroids 
PROLONGATION OF PREGNANCY (VS) OUTCOME: 
Visser and Wallenburg97 in their study of 254 women with 
severe preeclampsia between 20 to 32 weeks reported mean 
prolongation of pregnancy was 14 days and perinatal mortality was 
20%. 
Hall et al14 reported in their study mean prolongation of 
pregnancy was 11 days and perinatal mortality was 24%. Odendaal et 
al90 reported mean prolongation of pregnancy was 7.1 days. 
In our study Out of 32 patients who had prolongation of 
pregnancy, 27(87.4%) patients had a prolongation of pregnancy ≤ 10 
days. Maximum prolongation was 25 days. Mean Number of days 
gained was 7 days with a range of 1 – 25 days. There was 9(28.1%) 
and 2(6.2%) fetal morbidity and mortality respectively. There were no 
still births.Two neonatal deaths occurred in patients who were 
delivered at 29 weeks.   
There were no maternal death in the expectant group of patients 
and 4(12.5%) patients had complications like Eclampsia, HELLP, 
ARF, PP Eclampsia. 
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POST OP BP CONTROL: 
In majority of the patients BP control was achieved within a 
week. Only 7 patients were discharged with antihypertensives. 
POSTPARTUM HOSPITALISATION: 
 Most of the women required hospitalisation for 2 to 3 weeks 
with a minimum of 7 days and a maximum of 31 days.Mean of 
postpartum hospital stay was 16 days. 
Prolonged hospitalisation in most of the women was for baby 
sake. In the study by D.R.Hall14 mean period of postpartum 
hospitalisation was 5 days. 
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SUMMARY 
• In our study there were 150 patients of early onset severe 
preeclampsia. 
• Most of them were in the age group of 21 – 30 years. 
• Most of them were Primi (66%) 
• Most of the women ,148 (98.6%) were booked. 
• Most of the women , 85 (56.7%) and 64(42.6%) belonged to 
socioeconomic class IV and V respectively. 
• Mean gestational age  at diagnosis was 31 weeks. 
• Only forty three (28.6%) of the women  had risk factors  
( gestational hypertension in previous pregnanacy and family 
history of hypertension). 
• Most patients had normal fundus. 
• There was a significant reduction in the rate of seizures who 
received magnesium sulphate as prophylaxis. 
• All patients received multidrug oral antihypertensives and 33 
women received parenteral antihypertensive in addition to oral. 
• Most of the women underwent termination after 32 weeks 
84(56%) 
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• 85.3% termination was done for maternal indication,14.7% for 
fetal indication. Most common cause being Imminent 
Eclampsia. 
• Though mode of delivery had no influence on fetal outcome, 
caesarean rate was higher which accounts to about 69% 
• 32 patients was treated under expectant management and the 
maximum prolongation was 25 days.Mean number of days was 
7 with a range of 1-25 days. 
• Majority of babies had apgar between 5 and 7 
• The mean birth weight is 1.43 kg. 
• 58(38.6%) women experienced complications. Eclampsia and 
abruption were highest accounting to 17(11.3%)  and 14(9.3%) 
• There were 6(4%) maternal death. The cause of maternal death 
were HELLP / DIVC (2),  AP Eclampsia with hypertensive 
failure (1),  AP Eclampsia with ARF(1) , pulmonary edema(1) , 
Abruption with DIVC(1). 
• 25(16.6%) were IUFDs, majority were in women who were  
referred as IUFDs 
• Total Perinatal death IUFD+SB+ND  45 
• Incidence of PNM Total PND /No of babiesX 100 30% 
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• Major cause for neonatal morbidity and mortality were 
prematurity and Respiratory distress syndrome. 
• Out of 32 patients who had expectant management there was 
9(28.1%) and 2(6.2%) fetal morbidity and mortality 
respectively. There were no maternal death, and 4(12.5%) 
patients had maternal  complications. 
• In majority of the patients BP control was achieved within a 
week 
• Most of the women required hospitalisation for 2 to 3 weeks 
with a minimum of 7 days and a maximum of 31 days. 
• Mean of postpartum hospital stay was 16 days. 
• Prolonged hospitalisation in most of the women was for baby 
sake 
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CONCLUSION 
Early onset severe preeclampsia is associated with significant 
maternal and fetal complications. 
Early booking is essential for better maternal and fetal outcome. 
Decision regarding termination of pregnancy has to be taken 
based on both maternal and fetal factors. In case of severe 
uncontrolled blood pressure with complications, termination should be 
done irrespective of fetal maturity. Good NICU improves the fetal 
prognosis. 
In selected cases expectant management in a tertiary care centre 
limit the impact of serious maternal and fetal complications. 
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PROFORMA 
 
NAME:    AGE:   IP NO: 
ADDRESS:      DOA: 
DOD: 
 
BOOKED/UNBOOKED:     LMP: 
EDD: 
 
PRESENTING  COMPLAINTS 
H/O Amenorrhea 
 
H/O Headache/epigastric pain/ blurring of vision/decreased  
Urine output. 
H/O Bleeding Pv/ Draining PV 
H/O Perception Of Fetal Movements. 
 
MENSTRUAL HISTORY 
Age at menarche; 
  Menstrual cycles: 
    LMP:      EDD: 
 
MARITAL HISTORY 
Married Since: 
 Consanguineous/ non consanguineous 
 
OBSTETRIC HISTORY 
GRAVIDA:  PARA:    ABORTION: 
LIVE:   DEATH: 
Immunisation: 
Previous Pregnancy: 
Present Pregnancy: 
1ST Trimester: 
2ND Trimester: 
3RD Trimester: 
Last child birth: 
 
PAST HISTORY 
 
Renal Disease Liver Disease/ Diabetes/ Epilepsy/RHD/Thyroid 
Disease/Bronchial Asthma 
FAMILY HISTORY 
Hypertension:    
Diabetes: 
Patient's  mother  had  preeclampsia / eclampsia: 
  
  
PERSONAL HISTORY 
 
DIET:    SLEEP:   BLADDER:   BOWEL: 
 
GENERAL EXAMINATION 
 
HT:   WT:    BMI: 
TEMP:   BP:    PR:    RR: 
Pallor / Icterus / Pedal Edema 
CVS:     Breast: 
RS:     Thyroid: 
      PER ABDOMEN: 
Size of uterus(in weeks): 
Acting/not acting: 
Presenting part: 
Engaged/ unengaged: 
FHR: 
     PER VAGINAL EXAMINATION: 
 
INVESTIGATIONS 
 
URINE INVESTIGATIONS: 
Urine  Albumin:  Sugar:  Deposits: 
BLOOD INVESTIGATIONS: 
HB:    PCV:   Platelets:   
TC:     DC:              
Blood Sugar: 
Blood  Urea: 
Serum Creatinine: 
Serum Bilirubin: 
SGOT:  
SGPT:    
Serum Uric Acid: 
Serum T.Proteins: 
Serum Albumin:   
Serum Electrolytes: 
 
FUNDUS: 
ULTRASOUND  OBSTETRICS: 
FETAL DOPPLER: 
 
 
TREATMENT GIVEN: 
 
ANTI HYPERTENSIVES; 
STEROIDS: 
MgSO4: 
OTHER: 
 
  
 
MODE OF DELIVERY: 
    
Spontaneous / Induced: 
If Induction 
   Mode of induction: 
 Time of induction: 
 Induction - delivery interval: 
Duration of Labour 
  1ST Stage:    Liquor: 
2ND Stage:    Placental  Weight: 
3RD Stage: 
Vaginal delivery: 
Caesarean section: 
If Caesarean, Indication: 
Placenta weight: 
 
COMPLICATIONS DURING DELIVERY 
 
NEONATE 
Alive / death: 
Term / preterm: 
Sex: 
Apgar 1 Min:  5 Min: 
Weight: 
 
POST PARTUM FOR 72 HRS 
 
Consciouness: 
Temp:  PR:  BP:  RR: 
Urine Output: 
BP Normalises  in: 
CVS:   RS:  CNS: 
P/A:     P/V: 
 
 
MATERNAL OUTCOME 
 
Alive / Death:    Morbidity: 
If Dead,   Cause Of Death: 
 
FETAL OUTCOME 
 
 Alive / Death:    Morbidity: 
 IUFD:      IUGR: 
 Still Birth: 
 
NO OF DAYS OF POST PARTUM HOSPITALISATION: 
 
  
S
.
N
o
 
N
a
m
e
 
A
g
e
 
i
n
 
Y
e
a
r
s
 
I
P
 
N
o
 
P
a
r
i
t
y
 
B
o
o
k
e
d
 
/
 
U
n
b
o
o
k
e
d
 
S
o
c
i
o
 
E
c
o
n
o
m
i
c
 
S
t
a
t
u
s
 
A
n
t
e
n
a
t
a
l
 
R
i
s
k
 
f
a
c
t
o
r
s
 
+
/
-
 
G
e
s
t
 
a
g
e
 
a
t
 
D
i
a
g
n
o
s
i
s
 
F
u
n
d
a
s
 
D
o
p
p
l
e
r
 
c
h
a
n
g
e
s
 
A
n
t
i
 
h
y
p
e
r
t
e
n
s
i
v
e
s
 
o
r
a
l
 
(
O
)
/
 
P
a
r
e
n
t
e
r
a
l
 
(
P
)
 
M
g
s
o
4
 
S
t
e
r
o
i
d
s
 
E
x
p
e
c
t
a
n
t
 
m
a
n
a
g
e
m
e
n
t
 
+
/
-
 
N
o
.
 
o
f
 
d
a
y
s
 
g
a
i
n
e
d
 
G
e
s
t
 
A
g
e
 
a
t
 
d
e
l
i
v
e
r
y
 
M
o
d
e
 
o
f
 
d
e
l
i
v
e
r
y
 
I
n
d
i
c
a
t
i
o
n
 
f
o
r
 
t
e
r
m
i
n
a
t
i
o
n
 
M
a
t
e
r
n
a
l
 
/
 
F
e
t
a
l
 
A
P
G
A
R
 
B
i
r
t
h
 
W
e
i
g
h
t
 
M
a
t
e
r
n
a
l
 
O
u
t
c
o
m
e
 
F
e
t
a
l
 
o
u
t
c
o
m
e
 
P
o
s
t
p
a
r
t
u
m
 
B
P
 
C
o
n
t
r
o
l
 
P
o
s
t
 
p
a
r
t
u
m
 
h
o
s
p
i
t
a
l
i
s
a
t
i
o
n
 
1 Devi 26 36259 P  B IV 
      
- 32+1    - 
      
+ O No Yes 
      
+ 25 36+2 LSCS   F 9 1.85    Normal   Normal 5 10 
2 Roja 25 865 M B IV 
      
+ 30    - 
      
- 
O 
+P Yes No 
      
- 
      
- 30 LSCS  M 6 900    Normal   DEATH 3 16 
3 Samundeshwari 23 1801 P  B IV 
      
- 26    - 
      
- O No No 
      
- 
      
- 26+1  VD  M 0 550    Normal   IUFD 3 7 
4 Mohana 26 2278 M B V 
      
- 33 
Gr 
I 
      
- 
O 
+P Yes No 
      
- 
      
- 33 LSCS  M 7 1.5   Eclampsia   Normal 4 20 
5 Priya 27 2362 M B V 
      
+ 33+4    - 
      
- O Yes Yes 
      
+ 2 33+6 LSCS  M 9 1.9    Normal   Normal 2 10 
6 Sathya 19 2473 P  B V 
      
- 28    - 
      
- O No No 
      
- 
      
- 28 LSCS  M 0 600  Eclampsia   Stillborn 5 10 
7 Suguna 36 1713 M B IV 
      
+ 30    - 
      
- O No Yes 
      
+ 14 32 LSCS  M 8 1.25    Normal IUGR/RDS 4 25 
8 Sangeetha 26 2995 P  B V 
      
- 33+3 
Gr 
I 
      
- 
O 
+P Yes Yes 
      
- 
      
- 33+3 LSCS  M 9 2    Normal   Normal 3 9 
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9 Revathy 23 4289 P  B V 
      
- 32 
Gr 
I 
      
- 
O 
+P Yes No 
      
- 
      
- 32 LSCS  M 6 1.2  Eclampsia   DEATH 14 20 
10 Pattu 18 3944 P  B V 
      
- 27    - 
      
- O No Yes 
      
+ 5 27+5 LSCS  M 6 1.4   Eclampsia IUGR/RDS 7 22 
11 Deepa 23 4537 P  B IV 
      
- 32 
 Gr 
I 
      
- O Yes Yes 
      
- 
      
- 32 LSCS  M 8 1.9 
Wound 
infection   Normal 5 12 
12 Tamilselvi 29 5731 M B V 
      
- 33    - 
      
- 
O 
+P Yes Yes 
      
- 
      
- 33 LSCS  M 8 1.6    Normal   IUGR 6 14 
13 Chithra 32 6176 M B IV 
      
+ 33    - 
      
- O Yes Yes 
      
+ 1 33+1 LSCS  M 8 1.75    Normal   Normal 5 23 
14 Kalaivani 26 6247 M B V 
      
- 32    - 
      
- O Yes Yes 
      
- 
      
- 32 LSCS  M 7 1.3    Normal  RDS/HIE2 4 15 
15 Premavathy 31 6408 P  B IV 
      
- 32    - 
      
- O No No 
      
- 
      
- 32+1 LSCS  M 7 1.6    Normal   Normal 12 18 
16 Bharani 29 6405 P B V 
      
- 27 
Gr 
II 
      
- O Yes No 
      
- 
      
- 27+1 LSCS M 0 500 ARF IUFD 20 28 
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17 Vimala 24 7673 P B IV 
      
- 33    - 
      
- O Yes No 
      
- 
      
- 33 LSCS M 8 2.2 Normal Normal 4 11 
18 Gayathri 23 7241 P B IV 
      
- 27    - 
      
+ O+P No Yes 
      
+ 8 28+1 LSCS F 7 1.2 Normal RDS 6 28 
19 Manjula 35 8119 M B IV 
      
- 28    - 
      
- O No Yes 
      
+ 1 28+1 LSCS M 8 1 Normal Normal 12 35 
20 Sivaranjani 21 8180 P B V 
      
+ 33+6 
Gr 
I 
      
- O Yes No 
      
- 
      
- 33+6 LSCS M 8 2 Normal Normal 6 10 
21 Selvi 19 10002 P UB IV 
      
- 28 
Gr 
I 
      
- O+P Yes No 
      
- 
      
- 28 LSCS M 4 900 
Wound 
infection DEATH 5 18 
22 Rajeshwari 19 10288 P B V 
      
- 33+5    - 
      
- O+P Yes No 
      
- 
      
- 33+5 LSCS M 8 2.3 Normal Normal 3 10 
23 Ramya 27 4756 M B V 
      
- 32    - 
      
- O No No 
      
- 
      
- 32 LSCS M 7 1.3 Abruption RDS/HIE 1 4 25 
24 Tamilarasi 37 4835 M B IV 
      
+ 31    - 
      
+ O No Yes 
      
+ 21 34 LSCS F 7 1.2 Normal Normal 5 19 
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25 Vijayalakshmi 24 5008 P B IV 
      
- 33 
Gr 
II 
      
- O No No 
      
+ 5 33+6 LSCS M 7 1.45 Normal Normal 6 22 
26 Saroja 25 5411 P B V 
      
- 30+2    - 
      
- O Yes No 
      
- 
      
- 30+2 LSCS M 0 950 Normal IUFD 5 12 
27 Selvarani 26 11036 M B IV 
      
+ 32    - 
      
+ O No Yes 
      
+ 7 33 LSCS F 8 1.25 Normal IUGR 6 18 
28 Sridevi 18 12000 P  B IV 
      
- 33+1    - 
      
- O No Yes 
      
+ 5 33+6 LSCS M 8 2 Normal Normal 4 8 
29 Vinodhini 18 12951 P  B V 
      
- 30 
Gr 
I 
      
- O No No 
      
- 
      
- 30+1 VD F 0 750 Normal IUFD 3 7 
30 Saranya 20 13849 P  B IV 
      
- 32    - 
      
- O No Yes 
      
+ 2 32+2 LSCS M 9 2 Normal Normal 6 12 
31 Amudha 21 13966 P  B IV 
      
- 32 
Gr 
II 
      
- O+P Yes No 
      
- 
      
- 32 LSCS M 9 2.2 
Wound 
infection Normal 4 15 
32 Sathya 23 14332 M B IV 
      
+ 32 
      
- 
      
- O+P Yes No 
      
- 
      
- 32 LSCS M 6 1.3 Normal IUGR 6 17 
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33 Zeenua Vahan 19 14784 P B V 
      
- 31 
      
- 
      
- O No Yes 
      
+ 4 31+4 LSCS M 8 1.8 Normal Normal 5 10 
34 Punitha 20 15208 P B IV 
      
- 33 
      
- 
      
- O No No 
      
- 
      
- 33 LSCS M 8 1.8 Abruption RDS 4 12 
35 Sumathy 21 32057 P B IV 
      
- 33 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 33+1 LSCS M 8 1.8 
HELLP / 
DIC Normal 7 28 
36 Kanniyamal 28 15765 P B V 
      
- 32+4 
      
- 
      
- O No Yes 
      
- 
      
- 32+5 VD M 4 1.8 
 PP 
Eclampsia RDS 20 35 
37 Sumithra 28 15623 M B IV 
      
- 30 
Gr 
I 
      
- O Yes No 
      
- 
      
- 30 LSCS M 4 880 Normal  DEATH 4 12 
38 Sumathy 20 15329 P B V 
      
- 28+4 
Gr 
II 
      
- O+P Yes No 
      
- 
      
- 28+4 VD F 0 800 Normal IUFD 6 10 
39 Andal 32 15735 M B IV 
      
- 30 
      
- 
      
- O No Yes 
      
+ 7 31 LSCS M 8 1.65 HELLP  Normal 5 20 
40 Meena 29 16632 P B V 
      
+ 33 
Gr 
II 
      
- O+P Yes 
      
No 
      
- 
      
- 33 LSCS M 7 2 Abruption Normal 3 12 
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41 Radha 23 16660 P B IV 
      
- 30+1 
      
- 
      
- O Yes Yes 
      
- 
      
- 30+2 VD M 5 1.2 Normal 
RDS / 
IUGR 5 20 
42 Kalaiarasi 22 16598 P B V 
      
- 33 
      
- 
      
- O No Yes 
      
+ 5 33+5 LSCS F 8 2 Normal Normal 4 12 
43 Godavani 28 17415 M B IV 
      
- 30 
Gr 
I 
      
- O+P Yes No 
      
- 
      
- 30 VD F IUFD 800 Normal IUFD 3 10 
44 Anjalai 18 17708 P B V 
      
- 33 
      
- 
      
- O Yes Yes 
      
- 
      
- 33 LSCS M 5 2 Normal 
HIE2 / 
Asphyxia 14 18 
45 Sudha 23 17715 P B IV 
      
- 32+1 
Gr 
II 
      
- O+P Yes No 
      
- 
      
- 32 VD M IUFD 1.6 Normal IUFD 4 7 
46 Usha 25 16832 P B IV 
      
- 33+5 
      
- 
      
- O Yes No 
      
- 
      
- 33+5 LSCS M 9 2.3 
Wound 
infection Normal 6 22 
47 Devi 25 18606 P  B V 
      
- 33 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 33 VD M 3 1.6 Normal Death 5 10 
48 Radha 28 19227 M B IV 
      
+ 32 
Gr 
I 
      
- O+P Yes No 
      
- 
      
- 32 VD M 9 2 Normal Normal 11 14 
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49 Sudha Sree 20 19361 P B IV 
      
- 32 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 32+1 VD M 6 1.2 Normal IUGR 6 22 
50 Thiruveni 23 20403 P B V 
      
+ 33+4 
Gr 
I 
      
- O No No 
      
- 
      
- 33+4 VD F 0 1.2 Normal IUFD 4 9 
51 Selvi 36 20638 M B IV 
      
+ 28 
      
- 
      
- O No Yes 
      
+ 14 30 LSCS M 7 1.6 Normal IUGR 12 20 
52 Nagammal 23 21301 P B V 
      
- 33+5 
Gr 
I 
      
- O Yes No 
      
- 
      
- 33+5 LSCS M 0 1.6 Abruption IUFD 7 14 
53 Rani 23 21155 P B V 
      
- 31 
      
- 
      
- O+P Yes No 
      
- 
      
- 31 LSCS M 5 1.4  Eclampsia 
RDS / 
HIE2 4 15 
54 Renuka 23 21311 P B IV 
      
- 33 
      
- 
      
- O+P Yes No 
      
- 
      
- 33 VD M 7 1.6  Eclampsia Normal 6 17 
55 Arivuselvi 21 21573 P B IV 
      
- 31 
      
- 
      
- O Yes Yes 
      
- 
      
- 31+1 Lscs M 8 1.5 Normal Normal 31 12 
56 Valli 21 22014 P B V 
      
- 30 
Gr 
I 
      
- O No No 
      
- 
      
- 30 VD F IUFD 1.05 Normal IUFD 4 10 
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57 Gowri 32 22109 M B IV 
      
+ 33 
      
- 
      
- O No Yes 
      
+ 3 33+3 LSCS M 8 2.1 ARF Normal 7 25 
58 Rajathi 23 23095 P B IV 
      
+ 33 
Gr 
II 
      
- O+P Yes No 
      
- 
      
- 33 LSCS M 8 1.6  Eclampsia IUGR 5 14 
59 Kanikkai 25 23526 M B V 
      
- 30 
      
- 
      
+ O No Yes 
      
+ 5 30+5 LSCS F 7 1.2 Normal IUGR  6 25 
60 Shanthy 40 22877 P B IV 
      
- 33 
      
- 
      
- O Yes No 
      
- 
      
- 33 LSCS M 8 1.5 Normal 
RDS / 
HIEI 5 12 
61 Esther 26 24144 P B IV 
      
- 32 
      
- 
      
- O No No 
      
- 
      
- 32  VD F 0 1 Normal IUFD 6 11 
62 Amudha 29 25411 M B V 
      
+ 33 
      
- 
      
- O Yes Yes 
      
- 
      
- 33 LSCS M 7 1.7 Normal Normal 5 12 
63 Jayalakshmi 28 25621 M B V 
      
+ 33 
      
- 
      
- O Yes No 
      
- 
      
- 33 LSCS M 8 1.6 Atonic PPH IUGR 6 14 
64 Latha 29 25822 M B IV 
      
- 33 
      
- 
      
- O No No 
      
- 
      
- 33 LSCS M 0 1.4 Abruption IUFD 3 13 
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65 Geetha 22 26033 P B IV 
      
- 32 
      
- 
      
- O Yes No 
      
- 
      
- 32 LSCS M 7 1.2 Normal IUGR 5 14 
66 Amudha 29 25411 M B IV 
      
+ 33 
      
- 
      
- O No Yes 
      
- 
      
- 33 LSCS M 7 1.7 Normal Normal 7 15 
67 Jayalakshmi 28 25621 M B V 
      
- 33 
      
- 
      
- O Yes No 
      
- 
      
- 33 LSCS M 8 1.6 
Wound 
infection 
IUGR, 
RDS 6 21 
68 Latha 32 25822 M B IV 
      
+ 31 
Gr 
I 
      
- O No No 
      
- 
      
- 31 LSCS M 0 1.2 Abruption IUFD 5 13 
69 Geetha 22 26033 P B IV 
      
- 32 
      
- 
      
- O No Yes 
      
+ 7 33 LSCS M 8 1.6 Normal Normal 7 15 
70 Ansarbee 23 26589 P B IV 
      
- 32+1 
Gr 
I 
      
- O+P Yes No 
      
- 
      
- 32+1 VD M 6 1.4 Normal 
IUGR / 
RDS / 
HIEI 3 14 
71 Divya 21 26832 M B IV 
      
+ 26+4 
      
- 
      
- O No Yes 
      
+ 20 29+3 VD M 5 1 Normal  DEATH 8 22 
72 Kasthari 27 26629 M B IV 
      
- 32 
Gr 
I 
      
- O No No 
      
- 
      
- 32 VD M 0 1.3 Abruption IUFD 4 26 
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73 Rajeshwari 31 26328 M B V 
      
+ 30 
      
- 
      
- O+P Yes Yes 
      
- 
      
- 30+1 VD F 7 1.03 Normal Normal 7 18 
74 Maheswari 27 24439 P B IV 
      
- 32+5 
      
- 
      
- O No No 
      
- 
      
- 32+5 VD F 0 1.5 Normal IUFD 3 10 
75 Mary 19 27157 P B IV 
      
- 33 
      
- 
      
+ O No Yes 
      
+ 3 33+3 LSCS F 7 1.75 Normal Normal 4 15 
76 Prasanna 21 27321 M B IV 
      
+ 33 
Gr 
I 
      
- O+P Yes No 
      
- 
      
- 33 LSCS M 0 1.8 Abruption IUFD 3 20 
77 Chithra 32 28321 P B IV 
      
+ 25 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 25 VD M 0 800 Normal IUFD 4 13 
78 Vanitha 25 28360 P B IV 
      
- 33+5 
      
- 
      
- O+P Yes 
      
No 
      
- 
      
- 33+5 LSCS M 8 1.5 Normal 
RDS / 
Seizures 5 20 
79 Jayashree 25 28168 P B IV 
      
- 32 
Gr 
I 
      
- O Yes No 
      
- 
      
- 32+2 LSCS M 7 1.2 
DIVC / 
Relaprotomy Death 12 35 
80 Durga 19 28458 P B IV 
      
- 33 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 33 LSCS M 8 1.95 
Wound 
infection Normal 7 22 
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81 Anitha 22 28329 P B IV 
      
- 32 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 32 VD F IUFD 1 Normal IUFD 5 10 
82 Vanaja 24 28720 M B IV 
      
- 33 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 33 LSCS M 8 1.5 Normal 
RDS / 
HIEI 6 22 
83 Lakshmi 22 29578 M B V 
      
- 33+4 
Gr 
II 
      
- O+P Yes 
      
No 
      
- 
      
- 33 LSCS M 4 1.4 
HELLP, 
DIVC Death 8 20 
84 Srividhya 25 30193 M B IV 
      
+ 31+5 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 31+5 VD M 6 1.2 Normal 
IUGR / 
Septicemia 6 25 
85 Indhumathi 21 30232 M B IV 
      
- 33+4 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 33+4 LSCS M 8 1.5 Normal Normal 4 15 
86 Kanagavalli 21 30805 M B IV 
      
+ 33+5 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 33+5 VD M 7 1.7  Eclampsia Normal 5 13 
87 Saranya 27 28589 P B IV 
      
- 33 
Gr 
II 
      
- O Yes 
      
No 
      
- 
      
- 33 LSCS M 8 2 Death Normal   
Admission 
- Death 
Inteval 24 
hrs 
88 Mala 27 32385 M B V 
      
- 33+5 
      
- 
      
- O+P Yes 
      
No 
      
- 
      
- 33+5 LSCS M 3 1.6 Death Death   36 
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89 Sharmila 22 18775 P B IV 
      
- 30 
Gr 
I 
      
- O Yes 
      
No 
      
- 
      
- 30 LSCS M 0 1 Death Death   12 
90 Dhanalakshmi 19 7587 P B V 
      
- 31 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 31 LSCS M 0 1.2 Death Stillborn   5 
91 Jothi 34 3586 M B IV 
      
+ 32 
Gr 
II 
      
- O+P Yes 
      
No 
      
- 
      
- 32 LSCS M 0 1.25 Death IUFD   1d 6hrs 
92 Sethamilselvi 28 385 P B V 
      
- 30 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 30 VD M 0 1 Death IUFD   1d 12hrs 
93 Karthika 23 19934 P B III 
      
- 28+4 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 28+4 VD M 3 900 Normal Death 7 11 
94 Monika 20 32093 P B IV 
      
- 31+3 
      
- 
      
- O+P Yes 
      
No 
      
- 
      
- 31+3 LSCS M 0 1.3 Normal Stillborn 4 14 
95 Dhanalakshmi 24 32079 P B V 
      
- 33+5 
      
- 
      
- O Yes Yes 
      
- 
      
- 33+6 LSCS M 8 1.7 Normal Normal 5 14 
96 Kanagavalli 21 30895 M B IV 
      
+ 33+3 
Gr 
I 
      
- O+P Yes Yes 
      
- 
      
- 33+4 VD M 6 1 Normal  DEATH 4 7 
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97 Usha 25 16832 P B V 
      
- 33+5 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 33+5 LSCS M 7 1.5 Eclampsia 
IUGR / 
RDS 5 14 
98 Ramya 21 32760 P B V 
      
- 29+1 
      
- 
      
- O+P Yes Yes 
      
- 
      
- 29+2 LSCS M 8 1.25 Normal Normal 4 16 
99 Gomathi 32 35695 M B IV 
      
+ 32+2 
Gr 
I 
      
- O No Yes 
      
- 
      
- 32+2 VD M 0 700 Normal IUFD 3 7 
100 Saranya 19 12368 P B V 
      
- 28 
      
- 
      
- O No Yes 
      
+ 4 28+4 LSCS M 6 1.05 Normal 
RDS, 
Septicemia 5 21 
101 Saraswathi 22 16832 P B IV 
      
- 30+2 
      
- 
      
- O Yes Yes 
      
+ 3 30+5 LSCS M 7 1.3 
PP 
Eclampsia RDS 6 14 
102 Vimala 18 17829 P B V 
      
+ 27+2 
      
- 
      
- O Yes No 
      
- 
      
- 27+2 VD M 4 1 Eclampsia Death 5 14 
103 Vaideki 35 18321 M B IV 
      
+ 33 
      
- 
      
- O Yes Yes 
      
- 
      
- 33 VD M 7 1.6 Normal 
RDS, 
CPAP 4 20 
104 Malathi 23 16324 P B V 
      
- 32 
      
- 
      
- O Yes No 
      
- 
      
- 32 LSCS M 6 1.5 Eclampsia Normal 6 20 
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105 Niranjana 25 18392 P B IV 
      
- 33+3 
      
- 
      
- O Yes No 
      
- 
      
- 33+3 LSCS M 5 1.4 Normal IUGR 10 16 
106 Banu 19 19342 P B V 
      
+ 32 
      
- 
      
- O Yes Yes 
      
- 
      
- 32+1 LSCS M 6 1.5 Normal 
HIE2 / 
Septicemia 5 18 
107 Chandra 24 20012 P B IV 
      
- 33+5 
      
- 
      
- O Yes No 
      
- 
      
- 33+5 LSCS M 5 1.4 Normal RDS 6 21 
108 Shanthi 20 20132 P B IV 
      
- 28 
      
- 
      
- O+P No Yes 
      
+ 10 29+3 VD M 6 1 Normal RDS, HIE2 5 25 
109 Shyalaja 27 8679 P B V 
      
- 32 
      
- 
      
- O Yes No 
      
- 
      
- 32+1 VD M 7 1.6 Normal Normal 5 20 
110 Dhanam 20 6623 P B IV 
      
- 33+1 
      
- 
      
+ O No Yes 
      
+ 3 33+4 LSCS F 7 1.8 Normal Normal 4 14 
111 Ezhilarasi 34 4329 M B IV 
      
+ 27 
Gr 
I 
      
- O No No 
      
- 
      
- 27 VD M 0 900 Abruption IUFD 4 12 
112 Fathima 28 32489 P B V 
      
- 32+5 
      
- 
      
- O Yes Yes 
      
- 
      
- 33+6 LSCS M 7 1.6 Normal Normal 10 16 
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113 Gomathy 20 23229 P B V 
      
- 32+5 
      
- 
      
+ O No Yes 
      
+ 2 33 LSCS F 7 1.7 Normal Normal 7 18 
114 Girija 29 23329 P B IV 
      
- 33 
      
- 
      
- O Yes Yes 
      
- 
      
- 33+1 VD M 6 1.5 Normal Normal 6 21 
115 Astalakshmi 23 23369 P B V 
      
- 33+5 
      
- 
      
- O Yes Yes 
      
+ 2 34 LSCS M 7 1.6 Normal Normal 5 16 
116 Amudha 24 24321 P B IV 
      
- 33 
      
- 
      
- O Yes Yes 
      
- 
      
- 33+1 VD M 7 1.7 Normal Normal 3 15 
117 Banumathy 32 35829 M B V 
      
+ 28 
Gr 
II 
      
- O+P Yes No 
      
- 
      
- 28 LSCS M 5 1 Eclampsia RDS, HIE 5 14 
118 Jaya 27 25889 M B IV 
      
- 33+5 
      
- 
      
- O Yes Yes 
      
- 
      
- 33+6 VD M 8 1.8 Normal Normal 4 13 
119 Kalpana 20 26821 P B V 
      
+ 26+3 
      
- 
      
- O Yes No 
      
- 
      
- 26+4 VD M 6 800 ARF  DEATH 10 35 
120 Jamuna 33 26991 P B V 
      
- 32+2 
      
- 
      
- O Yes Yes 
      
- 
      
- 32+3 LSCS M 7 1.7 Normal Normal 4 11 
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121 Kanimozhi 20 27112 P B IV 
      
- 33+6 
      
- 
      
+ O No Yes 
      
+ 5 34+4 LSCS F 7 1.6 Normal Normal 5 10 
122 Kalai 32 27331 M B V 
      
+ 33+5 
      
- 
      
+ O No Yes 
      
+ 2 34 LSCS F 8 0 Normal Normal 4 13 
123 Madhavi 32 28829 M B V 
      
+ 31 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 31 LSCS  M 6 1.5 Eclampsia RDS, HIE2 6 14 
124 Maheswari 28 28902 P B IV 
      
- 30 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 30 LSCS  M 0 1.4 Abruption IUFD 5 13 
125 Latha 33 29201 P B V 
      
- 32 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 32 VD  M 6 1.4 
Wound 
infection IUGR 5 14 
126 Revathy 26 29323 P B V 
      
- 31+5 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 31+5 LSCS  M 3 1.7 Abruption Death 4 12 
127 Priya 20 29414 P B IV 
      
+ 28 
      
- 
      
- O+P Yes Yes 
      
- 
      
- 28+2 LSCS  M 5 1.1 Normal 
HIE2, 
Septicemia 6 14 
128 Subha 25 29432 M B V 
      
- 32 
      
- 
      
- O Yes Yes 
      
- 
      
- 32+1 VD  M 6 1.5 Normal Normal 4 15 
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129 Lalitha 20 29621 P B IV 
      
- 31+6 
      
- 
      
- O Yes Yes 
      
- 
      
- 32+1 LSCS  M 7 1.5 Normal Normal 6 21 
130 Pappu 21 29843 P B IV 
      
- 32+6 
      
- 
      
- O Yes No 
      
- 
      
- 32+6 LSCS  M 7 2 Normal Normal 4 15 
131 Shoba 36 29991 M B V 
      
+ 26+3 
      
- 
      
- O+P Yes No 
      
- 
      
- 26+3 VD  M 6 1 
PP 
Eclampsia 
HIE2, 
Septicemia 12 22 
132 Leelavathi 19 30102 P B V 
      
+ 33+1 
      
- 
      
+ O Yes No 
      
- 
      
- 33+1 LSCS  M 7 1.8 Normal Normal 5 14 
133 Sandhya 23 30221 P B IV 
      
- 33+3 
      
- 
      
- O No Yes 
      
+ 4 34 LSCS F 7 1.7 Normal Normal 6 13 
134 Santhi 34 30289 M B V 
      
- 33+6 
      
- 
      
- O Yes No 
      
- 
      
- 33+6 LSCS  M 6 1.8 Normal Normal 3 16 
135 Pavithra 28 31832 P B IV 
      
+ 27+5 
      
- 
      
- O No No 
      
- 
      
- 27+5 VD  M 0 900 Abruption IUFD 3 14 
136 Lakshmi 20 31419 P B IV 
      
- 32+6 
      
- 
      
+ O No Yes 
      
+ 2 33+1 LSCS F 7 1.7 Normal Normal 4 18 
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137 Meena 29 31278 M B V 
      
+ 33+1 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 33+1 LSCS  M 7 1.6 Normal Normal 5 12 
138 Renuka 31 32287 M B IV 
      
- 33+2 
      
- 
      
- O Yes Yes 
      
- 
      
- 33+3 VD  M 7 1.5 Normal Normal 6 10 
139 Uma 18 32389 P B V 
      
- 33+5 
      
- 
      
- O Yes Yes 
      
- 
      
- 33+6 VD  M 7 1.6 Normal Normal 8 17 
140 Neelavathi 20 32410 P B V 
      
- 33+6 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 33+6 VD  M 7 1.5 Normal Normal 10 12 
141 Fathima 26 32520 P B IV 
      
+ 27+6 
      
- 
      
- O+P Yes 
      
No 
      
- 
      
- 27+6 LSCS  M 0 900 Eclampsia Stillborn 6 13 
142 Usha 31 32589 M B V 
      
+ 32 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 32 VD  M 6 1.3 Atonic PPH 
RDS / 
HIEI 4 15 
143 Pankajam 27 33321 P B IV 
      
- 33+5 
      
- 
      
- O Yes Yes 
      
- 
      
- 33+6 VD  M 7 1.3 Atonic PPH IUGR 3 14 
144 Chandra 31 34381 P B V 
      
- 33+3 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 33+3 LSCS  M 6 1.4 
Wound 
infection IUGR 4 16 
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145 Menaka 20 35621 P B IV 
      
- 32+5 
      
- 
      
- O Yes 
      
No 
      
- 
      
- 32+5 LSCS  M 3 1.3 Eclampsia 
IUGR, 
HIE2 5 21 
146 Kavitha 25 36829 P B V 
      
- 33+2 
      
- 
      
- O Yes No 
      
- 
      
- 33+2 LSCS  M 4 1.6 Ahruption 
HIE2, 
Septicemia 4 16 
147 Jothi 31 36921 M B IV 
      
+ 28 
      
- 
      
- O No Yes 
      
+ 7 29 VD  M 6 1.1 Normal  DEATH 6 18 
148 Nisha 17 37820 P B V 
      
- 33+4 
      
- 
      
- O Yes No 
      
- 
      
- 33+4 LSCS  M 0 1.2 Ahruption IUFD 3 13 
149 Hema 23 38921 P B IV 
      
- 32+6 
      
- 
      
- O Yes No 
      
- 
      
- 32+6 LSCS  M 5 1.5 Eclampsia 
HIE2 / 
IUGR 7 13 
150 Megala 20 39981 P B V 
      
- 33 
      
- 
      
- O Yes No 
      
- 
      
- 33 LSCS  M 7 1.6 Eclampsia 
RDS, 
Septicemia 8 20 
  
KEY TO MASTER CHART 
 
P Primigravida 
M Multigravida 
B Booked 
UB Unbooked 
O Oral antihypertensive 
P Parenteral antihypertensive 
VD Vaginal delivery 
LSCS Lower segment caesarean 
section 
M Maternal 
F Fetal 
IUGR Intra Uterine Growth 
Restriction 
IUFD Intra Uterine Fetal Demise 
RDS Respiratory distress syndrome 
HIE Hypoxic ischaemic 
enchelopathy 
 
  
  
ABBREVIATIONS 
 
CRP C Reactive protein 
BMI Body Mass Index 
MAP Mean Arterial Pressure 
HCG Human Chorionic 
Gonadotrophin 
MSAFP Maternal Serum alpha 
fetoprotein 
HELLP Hemolysis, Elevated Liver 
Enzymes, Low Platelet count  
IUGR Intra Uterine Growth 
Restriction 
GA Gestational Age 
ARF Acute Renal failure 
DIVC Disseminated Intravascular 
Coagulation  
IUFD Intra Uterine Fetal Demise 
PNM Perinatal Mortality 
SB Stillbirth 
PND Perinatal death 
RDS Respiratory distress 
syndrome 
HIE Hypoxic ischaemic 
enchelopathy 
PP ECLAMPSIA Post partum eclampsia 
 
